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Abstract
Background: Recent evidence suggests that the IL-33/IL1RL1 axis plays a critical role in several autoimmune and
inflammatory disorders; however, its mechanistic role in inflammatory bowel disease (IBD) has not been clearly defined. We
investigated the contribution of IL-33 and IL1RL1 polymorphisms to IBD risk, and possible correlations with phenotype in an
Italian cohort of adult and pediatric patients.
Methods: We evaluated the association of six SNPs in IL-33 and IL1RL1 genes, in 805 Crohn’s disease (CD), 816 ulcerative
colitis (UC), and 752 controls, using Taqman. IL-33 and IL1RL1 mRNA expression was also analyzed.
Results: Significant allele and genotype associations with IL-33 rs3939286 were found in CD (P= 0.004; P = 0.035) and UC
patients (P= 0.002; P= 0.038). After stratifying the cohort for age at diagnosis, the differences remained significant only in
the IBD adult-onset. Significant associations were also obtained in CD patients with two IL1RL1 polymorphisms (rs13015714
and rs2058660, P,0.015). By combining homo- and heterozygous carriers of the rs13015714 risk allele, differences were still
significant for both CD adult- and pediatric-onset. Upon genotype-phenotype evaluation, an increased frequency of
extensive colitis in adult UC (P= 0.019) and in steroid-responsive pediatric patients (P= 0.024) carrying the IL-33 rs3939286
risk genotype, was observed. mRNA expression of IL-33 and IL1RL1 in inflamed IBD biopsy samples was significantly
increased.
Conclusions: Common IL-33 and IL1RL1 polymorphisms contribute to the risk of IBD in an Italian cohort of adult and
pediatric patients, with some influence on sub-phenotypes.
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Introduction
Intestinal mucosal inflammation is a highly regulated process,
with a wide repertoire of pro- and anti-inflammatory molecules
mediating distinct phases of gut immune responses. Pathologic,
chronic intestinal inflammation may arise from an imbalance
between different players within this process. As such, the onset
and perpetuation of gut inflammation, characterizing inflamma-
tory bowel diseases (IBD), namely Crohn’s disease (CD) and
ulcerative colitis (UC), are triggered by constitutive dysregulation
of cytokine production [1]. Indeed, a wealth of data indicates the
importance of genetic background in regulating the cytokine
network in IBD; in fact, polymorphisms of cytokine/cytokine
receptor genes have been shown to be associated with the
development of IBD [2,3,4]. For instance, several studies point out
the associations of IBD with genetic polymorphisms involved in
the signaling pathway of interleukin (IL)-1 family members, such
as IL-1b [5], IL-1 receptor antagonist [6], and IL-18 [7,8,9].
IL-33 is a newly characterized cytokine belonging to the IL-1
family with the ability to induce Th2 cytokine production [10] and
enhance both Th1 and Th2 [11], as well as Th17 immune
responses [12,13] IL-339s effects are mediated through the binding
of its receptor, IL-1 receptor like 1 (IL1RL1) or T1/ST2, and co-
receptor, the IL-1 receptor accessory protein (IL1RAcP), both
belonging to the Toll/IL-1 receptor (TIR) superfamily [14].
Several lines of evidence demonstrate the pathogenic role of IL-33
in numerous immune and inflammatory diseases, such as asthma
[15], rheumatoid arthritis [12], multiple sclerosis [16] and
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anaphylaxis [17]. In addition, IL-33 may have dichotomous
functions during inflammation, as it has been shown to be
protective in a few inflammatory-related conditions, including
atherosclerosis [18] and hepatitis [19]. Moreover, genetic dysreg-
ulation of the IL-33/IL1RL1 axis appears to be involved in
conferring predisposition to several multifactorial diseases, such as
Alzheimer’s disease [20], asthma [21,22,23], nasal polyposis [24],
allergic rhinitis [25], and atopic dermatitis [26].
Recently, several independent researchers have described
marked alterations of IL-33 and IL1RL1 expression in IBD
[27,28,29,30,31]. These studies, although focusing on different
aspects, consistently demonstrated the upregulation of IL-33 in the
inflamed colonic mucosa of IBD patients, with a greater
prevalence in UC. Despite the aforementioned evidence suggest-
ing involvement of the IL-33/IL1RL1 axis in the pathologic events
leading to the development of IBD, no definitive data regarding
the precise role of IL-33 during intestinal inflammation are
available.
In the present study we aimed to establish the role of IL-33 and
IL1RL1 genes in the risk of developing IBD in a well-characterized
Italian cohort of adult and early onset IBD patients (805 CD and
816 UC), either by genotyping or by functional studies. Herein, we
describe for the first time, the association between the rs3939286
IL-33 polymorphism with both UC and CD, and between variants
of IL1RL1 with CD. Of note, the aforementioned SNP was also
associated with specific clinical UC sub-phenotypes. Taken
together, our data further suggest the involvement of IL-33 in
the pathogenesis of IBD and provide insight into its possible role in
the clinical features of chronic intestinal inflammation.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee of ‘‘Casa
Sollievo della Sofferenza’’ Hospital, San Giovanni Rotondo, and a
voluntary written informed consent was obtained from all adult
participants and related parents of patients under 19 years of age.
Patient Recruitment
Demographic and clinical of the Italian IBD patients and
controls are shown in Table 1. The study group (n = 2373)
consisted of 805 CD patients, 816 UC patients, and 752 healthy
individuals as controls. 303 IBD patients had the initial diagnosis
of IBD before their 19th year (155 CD and 148 UC).
Patients with diagnosis of CD or UC were included in the study
based on clinical, endoscopic, and histologic findings according to
the Montreal Classification [32]. All individuals were enrolled
prospectively from the Gastroenterology Unit at the IRCCS
‘‘Casa Sollievo della Sofferenza’’ Hospital, San Giovanni Ro-
Table 1. Clinical and demographic characteristics of the
study population.
CD n=805 UC n=816
Gender
F 321 40% 344 42%
M 484 60% 472 58%
Duration of follow-up (yr)
mean 6 SD 867 967
median 6 SD 6 (1–37) 7 (1–41)
Age at diagnosis (yr)
mean 6 SD 30614 32616
median 6 SD 28 (1–80) 30 (1–75)
Early onset (,19 yrs) 155 20% 148 19%
Adult ($19 yrs) 622 80% 640 81%
Missing 28 28
#16 (A1) 130 17% 125 16%
17–40 (A2) 483 62% 456 58%
.40 (A3) 164 21% 207 26%
Missing 28 28
Disease localization CD, n
Ileum (L16 L4) 256 36%
Colon (L26 L4) 171 24%
Ileo-colon (L36 L4) 286 40%
Upper GI (L4) 6 1%
Missing 86
Disease extent UC, n
Rectum (E1) 95 12%
Left colon (E2) 374 47%
Pancolitis (E3) 322 41%
Missing 25
Disease behavior CD, n
Inflammatory 475 61%
Stricturing 209 27%
Penetrating 94 12%
Missing 27
Perianal desease y/n 143/630 18% 20/765 3%
Missing 32 31
Extra-intestinal manifestations y/n 327/446 42% 194/554 26%
Missing 32 68
Family history of IBD y/n 55/725 7% 64/729 8%
Missing 25 23
Smoking history
Yes 229 30% 110 14%
No 402 53% 444 57%
Ex 127 17% 222 29%
Missing 47 40
Surgery y/n 258/527 33% 77/711 10%
Missing 20 28
Steroids y/n 510/295 63% 514/302 63%
*Refractory 73 14% 71 14%
*Responder+dependent 433 86% 438 86%
Table 1. Cont.
CD n=805 UC n=816
IMS (AZT/6MP, CICLO, MTX)
Yes 302 38% 217 27%
No 503 62% 599 73%
Non Responder 17 15% 3 23%
Responder 96 85% 10 77%
*Steroids_Resp-DepvsRefrac.
CD: Crohn’s disease, UC: ulcerative colitis, IMS: immunosuppressors.
doi:10.1371/journal.pone.0062144.t001
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tondo, from centers of the Italian Group of IBD (IG-IBD), and
from pediatric centers of the Italian Society of Pediatric
Gastroenterology, Hepatology and Nutrition (SIGENP). Clinical
data for IBD patients were obtained retrospectively from clinical
files. The control group consisted of blood donors and healthy
individuals without history of immune-mediated diseases.
Biopsy Collection
Overall, 29 patients with active IBD, including 15 CD and
14 UC, were used in the present study. Mucosal colonic biopsies
were obtained from adult patients undergoing routine colonoscopy
at the IRCCS ‘‘Casa Sollievo della Sofferenza’’ Hospital, San
Giovanni Rotondo. The activity of disease was evaluated by the
Harvey-Bradshaw score (HBI) for CD, and the Mayo score for
UC. After obtaining written informed consent, patients with an
HBI .4 and a Mayo score .3 were enrolled. Biopsies were taken
from inflamed and adjacent non-inflamed regions (10–15 cm
distant from pathologic areas). Unaffected areas were defined as
mucosal regions without any macroscopic/endoscopic signs of
inflammation (e.g., discoloration, hemorrhagic appearance, edema,
ulceration, or mucinous/fibrinous coating).
Selection of Tagging Single Nucleotide Polymorphisms
(tSNPs) and Genotyping
The selection of SNPs for the present study was made
considering previous association studies and the position of the
SNPs in the IL-33 and IL1RL1 genes. IL-33 and IL1RL1 tSNPs
were selected using genotypic data from the Caucasian (CEU)
Phase II study, available from the HapMap project (http://www.
hapmap.org) [33]. SNPs were identified using Haploview software
version 4.2 [34] based on solid spine of linkage disequilibrium (LD)
(r2.0.8, haplotype frequency .5%, minor allele frequency
.10%).
This process identified three SNPs for the IL-33 gene:
rs3939286, rs7025417 and rs7044343 (Figure S1). The
rs3939286 SNP was reported to be associated with nasal polyposis
[24] and asthma [21]; the rs7025417 was chosen to tag haplotype
block 2; the rs7044343 was selected based on its association with a
decreased risk of developing Alzheimer’s disease [20] and in high
LD (r2.0.8) with the tag SNP rs10975514 of the block 3. By
contrast, the significant SNP identified in the CD and UC
genome-wide meta-analysis [35,36,37] was rs10758669, located at
4.97 Mb on chromosome 9p24 encompassing the JAK2 gene, with
a distance of 1.23 Mb from the selected rs3939286 (6.20 Mb)
(Figure S2). The three selected SNPs for the IL1RL1 gene on
chromosome 2q12 were rs2058660, rs2310173, and rs13015714
(Figure S3, Figure S4). The rs2058660 has already been found
to be associated with CD [35]; and the rs2310173 was reported to
be associated with UC [36]. In addition, the rs13015714 was
found to be significantly associated with an increased risk for celiac
disease (2q11–12, IL18RAP) [38].
Genomic DNA was extracted from whole blood samples by a
standard non-enzymatic method, using the QIAamp DNA Blood
Maxi Kit (Qiagen GmbH, Hilden, Germany). Samples were
genotyped for the SNPs rs3939286, rs7025417, rs7044343,
rs2058660, rs2310173, and rs13015714 using 59exonuclease
TaqMan genotyping assays on an ABI Prism 7900 Real-Time
polymerase chain reaction (PCR) System, according to manufac-
turer’s instructions (Applied Biosystems, Foster City, CA). The
genotyping and data management were performed at the
Research Laboratory of Gastroenterology Unit of the IRCCS
‘Casa Sollievo della Sofferenza’ Hospital, San Giovanni Rotondo,
Italy.
IL-33 and IL1RL1 mRNA Quantification
Total RNA was extracted from biopsies using Trizol (Invitro-
gen, Paisley, UK) or RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. The amount of RNA was measured
by NanoDrop ND-1000 spectrophotometer (NanoDrop Technol-
ogies Wilmington, Delaware, USA). The integrity and quality of
isolated RNA was determined by Agilent Bioanalyzer 2100
(http://www.chem.agilent.com). In order to preserve the tran-
scriptional profile of tissue specimens, the biopsies were rapidly
transferred to RNAlater (Qiagen, Valencia, CA, USA) or snap-
frozen in liquid nitrogen and stored until RNA extraction.
Microarray Data Analysis
Total RNA from biopsy specimens (29 IBD patients) was
analyzed with the GeneChip Human Gene 1.0 ST Array System
(www.affymetrix.com), which interrogates 28,869 well-annotated
genes by using an average of 26 probes per gene. Each sample was
processed according to the manufacturer’s instructions. The
Affymetrix raw data (.CEL file) were generated using the
Affymetrix GeneChip Scanner 3000 7G and analyzed using
Partek Genomic Suite Software v. 6.6 (Partek Inc., St. Louis, MO).
Briefly, raw intensity values were imported by setting up robust
multiarray analysis (RMA) background correction, quantile
normalization, and log transformation. Principle component
analysis (PCA) was performed as it is an excellent method for
visualizing high-dimensional data and identifies outlier samples;
mixed model ANOVA was performed in order to generate a
comprehensive list of differentially-expressed genes by using a
cutoff of P,0.05 for significance of gene-level expression.
For the purpose of this study, we selected the microarray data
from all performed comparative analyses for the probe sets
encoding the IL-33 and IL1RL1 genes.
Statistical Analysis
Statistical analysis was performed using SPSS software version
14.0 (SPSS, Chicago, IL, USA) and Haploview Software version
4.1 (http://www.broad.mit.edu/personal/mpg/haploview). The
genotype frequencies for all investigated polymorphisms were
tested for consistency with the Hardy-Weinberg equilibrium.
Allelic and genotypic associations of SNPs were evaluated by
Pearson’s x2 test (or Fisher’s when appropriate) followed by odds
ratio and 95% CI. P-values of less than 0.05 were considered
significant. Linkage disequilibrium between markers, haplotype
structures and haplotype association analyses were also performed.
Univariate and logistic regression analyses, on forward stepwise
selection procedures, were carried out to correlate various clinical
parameters with genotypes and to study pairwise interactions
between SNPs of different genes using the number of risk alleles as
predictor variables.
Results
Case–control Study
The allele and genotype frequencies of the six IL-33/IL1RL1
SNPs (IL-33: rs3939286, rs7025417, rs7044343; IL1RL1:
rs2058660, rs2310173, rs13015714) were in accordance with the
predicted Hardy-Weinberg equilibrium in all subgroups (CD, UC,
and controls) (P.0.05).
The results for the whole study population are shown in
Tables 2,3.
Association between IL-33 Polymorphisms and IBD
The rs3939286 variant of the IL-33 gene is associated with
adult CD and UC patients. A significant allele and genotype
IL-33, IL1R1 and IBD
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association of SNP rs3939286 with CD [P = 0.004, OR 1.27
(1.07–1.50); P = 0.035, OR 1.24 (1.01–1.53), respectively] and
with UC [P = 0.002, OR 1.29 (1.09–1.52); P = 0.038, OR 1.24
(1.01–1.52), respectively] was observed. After stratifying the CD
and UC cohorts in different subgroups according to the age at
diagnosis (,19 and $19 years), the distribution of allele and
genotype frequencies of CD patients [P = 0.006, OR 1.28 (1.07–
1.53); P = 0.029, OR 1.27 (1.02–1.58), respectively], and allelic
frequencies of UC patients [P = 0.002, OR 1.30 (1.09–1.56)], in
comparison to that of control subjects, remained significant only
for the adult population (Tables 2,3). All other IL-33 SNPs
investigated in both diseases did not show any significant
differences in the allele and genotype frequencies in adult- and
early-onset IBD.
Association between IL1RL1 Polymorphisms and IBD
The rs13015714 and rs2058660 variants of the IL1RL1
gene are associated with CD patients. A significant differ-
ence in allele and genotype frequencies of the rs13015714 SNP in
CD population [P = 0.015, OR 1.23 (1.04–1.46); P = 0.008, OR
1.32 (1.07–1.62), respectively], adult-onset patients [P = 0.040, OR
1.21 (1.00–1.45; P = 0.039, OR 1.26 (1.01–1.57), respectively],
and early-onset patients [P = 0.021, OR 1.51 (1.06–2.16): geno-
type frequency], compared with controls, was observed. Analysis
of frequency distribution of the rs2058660 variant revealed
significant association with CD patients compared to controls
[allelic P = 0.015, OR 1.23 (1.04–1.46); genotypic P = 0.015, OR
1.29 (1.05–1.58)]. The same genotype was also slightly increased in
early-onset CD patients [P = 0.046, OR 1.43 (1.00–2.03)], with a
similar trend, not reaching statistical significance, in adult patients.
Similarly, allele frequency was significantly different in CD adult
patients [P = 3.4561022, OR 1.21 (1.01–1.45)] (Table 2). No
association was found between the IL1RL1 polymorphisms and the
risk of UC disease. However, at recessive model of inheritance, a
significant decreased frequency of the rs230173 IL1RL1 risk
genotype [P = 0.033, OR 0,77 (0.61–0.98)] was found compared
with healthy controls. This association remained significant in the
adult subgroup [P = 0.023, OR 0,74 (0.58–0.96)] (Table 3).
Association between IL-33 and IL1RL1 Polymorphisms
and Disease Phenotype
Analysis of genotype-phenotype was performed, interrogating,
in each patient, the following clinical features: gender, age at
diagnosis, IBD family history, smoking habit, severity and disease
localization, presence of perianal fistulas, extraintestinal manifes-
tations, previous abdominal surgery, use and response to medical
therapy (mesalamine, corticosteroids, immunosuppressive drugs,
azathioprine, 6-mercaptopurine, methotrexate, cyclosporine and
infliximab). Patients were classified as responder or non-responder
on the basis of a review of medical records as previously described
[39].
An increased frequency of extensive colitis (E3vsE1) was
observed in UC adult patients carrying the IL-33 rs3939286 risk
genotypes (AG+AA) (47% vs. 33%; P = 0.019) compared with
those carrying the GG wild-type genotype. Moreover, an
increased frequency of the risk genotype in steroid-responsive,
early-onset UC patients was also demonstrated (44% vs. 12%;
P = 0.024) (Table 4).
No other significant correlations of IL-33 and IL1RL1 genotypes
with either clinical features of patients with UC or efficacy of
medical therapy were found. In patients with CD, no significant
association of either IL-33 or IL1RL1 polymorphisms with any
clinical characteristics was demonstrated in both adult- and early-
onset patient subgroups.
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IL-33 and IL1RL1 Haplotype Analysis
No significant associations between either IL-33 or IL1RL1
haplotypes and disease risk was observed (Table S1).
IL-33 and IL1RL1 Expression
IL-33 and IL1RL1 mRNA levels in colonic IBD biopsy samples
revealed significant differences in UC and CD (Figure S5). In
CD patients, IL-33 mRNA transcripts were 1.81-fold significantly
increased in inflamed versus non-inflamed mucosa (P = 0.0033,
FDR = 0.05); in contrast, no significant change in IL1RL1 mRNA
expression was found. In UC patients, IL-33 and IL1RL1 mRNA
levels showed a significant increase (1.69 fold, P = 0.0012,
FDR = 0.03; 1.40-fold, P = 0.0009, FDR = 0.02, respectively) in
inflamed compared to non-inflamed areas.
When comparing the allele dosage with mRNA expression
profiles, no differences in IL-33 and IL1RL1 mRNA levels were
found (data not shown).
Discussion
Although the precise etiology remains unknown, it is thought
that IBD result from a dysregulated and aberrant immune
response to intestinal flora in the context of a genetic predispo-
sition. Moreover, an imbalance of pro- and anti-inflammatory
mediators is a critical factor in IBD pathogenesis [40]. Cytokines
are key regulators of the intestinal immune system and are known
to participate in the disruption of the so-called normal state of
controlled inflammation. Early, innate-type cytokines, primarily
secreted by the intestinal epithelium as well as activated antigen
presenting cells, including dendritic cells and macrophages,
actively regulate the inflammatory response in UC and CD.
These innate-type cytokines include members of the IL-1 family
and have the ability to trigger and differentiate T cells, activating
downstream adaptive immune responses. T cell dysregulation in
IBD is characterized by aberrant clearance of overreactive and
autoreactive cells and an imbalance of Treg/Th1, Th2 and Th17
cell populations. The lack of appropriate regulation from T cells,
and/or an over-reactive response from effector T cells, contributes
to the development and exacerbation of IBD [41].
Interleukin-33, a novel member of the IL-1 cytokine family [10],
has been shown to elicit a Th2- like cytokine response in
immunocompetent cells through binding and activation of the
interleukin 1 receptor-like 1 [42]. The IL-33/IL1RL1 pathway
plays an important role in host defense and in autoimmune,
allergic, and chronic inflammatory disorders, such as asthma,
dermatitis, rhinitis, arthritis, diabetes mellitus, atherosclerosis, and
Alzheimer’s disease [43]. Most recently, IL-33 has been associated
with allergic airway inflammation and arthritis in experimental
animal models [13,44]. Interestingly, blocking IL1RL1 receptor
signaling has been shown to prevent arthritis development and
airway inflammation [45,15].
The IL-33/IL1RL1 signaling axis has been implicated in IBD
in several studies reporting IL1RL1 and IL-33 protein and mRNA
expression in IBD patients [28]. An up-regulation of IL-33 in
human biopsy specimens, particularly from active UC patients
compared to controls was observed [27,28,29], identifying
epithelial cells, myofibroblasts and macrophages as primary
sources of IL-33 within the inflamed tissue of IBD patients.
Similarly, an increase in IL1RL1 levels in the gut, mainly
associated with the active state of UC, has been described,
together with elevated circulating levels of IL1RL1 and IL-33 in
IBD patients [28,29]; Pastorelli et al. also showed that anti-TNF
therapy modulated IL1RL1 and IL-33 serum levels, increasing theT
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soluble isoform of IL1RL1, making more decoy receptors
available, and reducing circulating IL-33 [29].
The research efforts of the IBD International Genetic Consor-
tium, by means of hypothesis-free genome wide association studies
(GWAs) [35,36,46] and Immunochip project [47], have led to the
identification of 163 genomic loci. The majority of loci (67%)
confer susceptibility to both Crohn’s disease and ulcerative colitis,
with only 30 loci thought to be specific for Crohn’s disease and 23
specific for ulcerative colitis. For almost all of these new loci, the
exact gene and/or causal variants remain to be determined.
However, GWAs do not have perfect coverage, as about 30% of
the common variants are not included on GWAs arrays, leaving
gaps that need to be filled by targeted association studies.
Moreover, the genetic susceptibility risk explained by GWAs loci
to date, is not much higher than 20%, compared with an estimated
overall genetic risk of about 40% (based on previous concordance
studies in twins) [34,48]. Of particular relevance to the present
study, IBD GWAs have identified genes related to innate
immunity as a critical component in the pathogenesis of IBD
[49–55]. In fact, several recent studies have attempted to
document the genetic overlap between IBD and various auto-
immune diseases, with approximately 51 IBD genes identified
overlapping 23 different diseases, such as multiple sclerosis,
rheumatoid arthritis, ankylosing spondylitis, psoriasis, asthma,
SLE, and celiac disease [56], yielding significant insight into
disease pathogenesis.
Thus, identification of the role of IL-33 and IL1RL1 in IBD
susceptibility is in line with the recent concept of shared genetic
determinants for clinically distinct disorders [57], and notwith-
standing the number of IBD susceptibility genes that has increased
dramatically over the last several years, genes associated with the
IL-33 signaling pathway have not been reported to date. In the
International IBD Genetics Consortium meta-analysis for CD and
UC, no associated SNPs in IL-33 were reported, while the
rs10758669 variant (position 4971602) of JAK2 was identified as a
CD and UC risk locus (CDmeta P = 1.00610
213, UCmeta
P = 8.52610213) [36]. Our selected SNPs in IL-33 are not in
LD with the reported rs10758669 variant (Figure S2). Although
the selected SNPs have not been reported in the meta-analysis, the
significant association with the rs3939286 variant and both CD
and UC, particularly in the adult population (P = 0.006 and
P = 0.002, respectively), implicates IL-33 as a novel IBD suscep-
tibility gene. Interestingly, this genetic association was also found
with the UC phenotype. Adult UC patient carriers of the
rs3939286 variant were at a higher risk of developing extensive
colitis compared to homozygous wild-type carriers (OR = 1.86).
Moreover, early-onset patient carriers of the IL33 rs3939286 risk
genotype were significantly more responsive to steroids (44%)
compared with noncarriers (12%) (OR = 5.32).
Furthermore, we were able to confirm high levels of IL-33
expressed in the inflamed mucosa of both UC and CD patients,
although the risk alleles did not influence the mRNA transcript
levels. These data confirm that IL-33 mRNA expression is
increased in UC and CD locally, within the colonic mucosa,
and are indication of active inflammation.
At present, despite the wealth of data indicating the prominent
alterations of IL-33/IL1RL1 expression in the inflamed mucosa of
IBD patients, no definitive data have demonstrated the precise role
of this axis during gut inflammatory conditions. Interestingly,
experimental data obtained using different animal models of
intestinal inflammation have produced conflicting results. In fact,
IL-33 was shown to potently increase the production of pro-
inflammatory cytokines, such as IL-5, IL-6 and IL-17, in SAMP1/
YitFc mice, a mixed Th1/Th2 spontaneous model of chronic
enteritis [30], whereas exogenous administration of IL-33 showed
a protective effect in trinitrobenzene sulfonic acid (TNBS)-induced
colitis, a chemically-induced model of colonic inflammation,
mostly driven by a Th1 immune response [58]. In addition, three
different groups demonstrated dichotomous functions of IL-33 in
the setting of acute dextran sodium sulphate (DSS)-induced colitis
[59–61]. Following epithelial barrier disruption caused by DSS
administration, IL-33 appeared to worsen colitis, inducing the
recruitment of neutrophils to the site of inflammation [59–61],
whereas, during the recovery phase, IL-33 showed a prominent
effect in promoting mucosal healing [59,61] and inducing goblet
cell proliferation [60], eventually restoring epithelial barrier
function.
The dichotomous role of the IL-33/IL1RL1 axis within the
context of chronic intestinal inflammation has been previously
proposed [62] and may explain the results obtained within the
present study regarding the association of the rs3939286
polymorphism of IL-33 with IBD and with specific UC
phenotypes. The rs3939286 polymorphism has been previously
shown to be associated with the development of Th2-driven
pathologic conditions, such as nasal polyposis, asthma and
systemic eosinophilia [21,22]. As such, it is likely that presence
of the rs3939286 polymorphism confers greater bioactivity to IL-
33, which is consistent with the exaggerated inflammatory
response that characterizes IBD. Moreover, during the onset of
UC, a disease mainly dominated by Th2 cytokines, the presence of
the rs3939286 variant further promotes a pathogenic Th2
response and may push the phenotype towards a more extensive
disease, such as pancolitis. On the other hand, during short term
anti-inflammatory treatment, as in the case of steroid treatment,
the production of pro-inflammatory cytokines is dampened; in this
Table 4. Association between IL-33 and rs3939286 polymorphism and disease phenotype.
Gene SNP Disease Phenotype
No. of patients
GG
No. of patients
AG+AA P value OR (95% CI)
IL-33 rs3939286 UC adult Localization
(E3 vs E1)
Extensive UC (E3) 125 (53%) 112 (47%) 0.019 1.86 (1.10–3.14)
Proctitis (E1) 56 (67%) 27 (33%)
UC early onset Steroids No 12 (32%) 26 (68%) 0.001 3.47 (1.57–7.64)
Yes 64 (62%) 40 (38%)
Steroids Refractory 14 (88%) 2 (12%) 0.024 5.32 (1.14–24.83)
Responder+Dependent 50 (56%) 38 (44%)
doi:10.1371/journal.pone.0062144.t004
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setting, the increased bioactivity of IL-33 may enhance the healing
of mucosal damage, improving the restoration of epithelial barrier
integrity, and favor the achievement of disease remission. Again,
this may be consistent with the association of the rs3939286
polymorphism to a steroid responsive phenotype, as indicated by
our results.
IL-33 exerts its biologic effects through binding of its receptor,
the formerly orphaned receptor IL1RL1, also called T1 or ST2
[10]. Two different splice variants of ST2 have been described
[63], leading to the synthesis of two different proteins: ST2L, a
transmembrane receptor that activates downstream signaling upon
IL-33 recognition, and sST2, a soluble molecule that likely serves
as a decoy receptor, ultimately blocking IL-33’s biologic effects.
The IL1RL1 gene is located on chromosome 2q12 and a number
of IL1 family members, namely IL1R2, IL1R1, IL1RL2, IL18
receptor 1 (IL18R1), and IL18 receptor accessory protein
(IL18RAP) reside in the immediate proximity of the IL1RL1 gene.
Interestingly, the IL18RAP gene was also recently shown to be
associated with celiac disease, a chronic inflammatory disease of
the small intestine with autoimmune features [38,64]. The region
spans about 300 kb and is in high linkage disequilibrium. There is
evidence for the involvement of genes surrounding IL1RL1 in
human and experimental disease, and therefore the causal locus
responsible for genetic association signals from this region is
difficult to determine. In fact, it is unclear at present whether the
CD-associated (rs2058660) and UC-associated (rs2310173) SNPs
in these regions tag two separate loci or one locus.
Our results demonstrate a significant difference in genotype
frequencies of the rs2058660 (P = 0.015) and rs13015714
(P = 0.008) SNPs in the IL1RL1 gene between CD patients and
controls. The differences were still significant for the rs13015714
risk allele for both adult- (P = 0.039) and early-onset disease
(P = 0.021). In addition, no significant changes in IL1RL1 mRNA
expression levels were found in CD biopsy samples; conversely, a
significant increase in IL1L1 mRNA transcripts from UC inflamed
biopsies was observed (1.40-fold, P = 0.0009, FDR = 0.02), without
influence of the allele dosage and the expression profiles.
Present literature does not provide robust hints about the
functional significance of IL1RL1 gene polymorphisms studied in
the present paper (rs2058660, rs2310173, rs13015714); thus, it is
not possible to speculate whether they lead to altered bioactivity of
IL1RL1 isoforms. However, our results, showing an association of
rs13015714 to CD, classically considered a Th1-driven disease,
but not UC, may suggest that the presence of this specific
polymorphism may impair the function of the IL-33/IL1RL1 axis.
As a consequence, in the presence of a predisposing genetic
background to IBD, the rs13015714 polymorphism may polarize
the intestinal inflammation towards a Th1-dominated CD
phenotype, rather than a Th2-dominated UC phenotype.
Interestingly, it has been recently demonstrated that, while IL-33
promotes Th2 cytokine production through IL1RL1 binding, it is
also capable of inducing non-polarized immune responses in an
IL1RL1-independent manner, implicating the existence of a
second IL-33 receptor or, more likely, the presence of IL-339s
direct effect on DNA-transcription [65] through the DNA-binding
domain possessed by this cytokine [66]. Therefore, it may be
hypothesized that the rs13015714 polymorphism impairs the
expression, or IL-33 binding capacity, of both IL1RL1 isoforms.
As a consequence, IL-33 may be ‘‘free’’ from its decoy receptor
and capable to exert its pro-inflammatory effects, eliciting a
IL1RL1-independent inflammatory program and leading to
susceptibility of a polarized Th1/Th17-mediated inflammatory
condition, such as that observed in CD. In fact, recent evidence
suggests that IL-33 has the ability to polarize immune responses
towards a Th17 profile in experimental models of arthritis [12,13].
Indeed, functional data regarding the effects of IL-339s
rs3939286 and IL1RL1’s rs13015714 polymorphisms on respec-
tive protein expression and bioactivity are needed to confirm these
assumptions, solely based on disease and phenotype associations.
Taken together, our data suggest that risk variants in the IL-33/
IL1RL1 system may influence IBD disease susceptibility, partic-
ularly in adult populations, and further support the importance of
the IL-1 family of cytokines in the predisposition to both CD and
UC. Moreover, a specific imbalance between IL-33 and IL1RL1
may play a pathogenic role in this process. The associations
between the IL-33 rs3939286 polymorphism and IBD, and
between the IL1RL1 rs13015714 and CD, further support the
overlap in susceptibility loci/genes between IBD and other
immune-mediated diseases. Of note, the aforementioned SNPs
were reported to be associated with nasal polyposis [24], asthma
[21] (rs3939286), and celiac disease [38] (rs13015714). Further
investigation as well as targeted functional studies are needed to
understand how IL-33 and IL1RL1 variants contribute to disease
susceptibility in IBD, and whether presence of these polymorphic
markers might have clinical therapeutic implications.
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